PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD 490.50
-7.50 (-1.51%)
Apr 24, 2025, 1:30 PM CST
PharmaEssentia Revenue
In the year 2024, PharmaEssentia had annual revenue of 9.73B TWD with 90.67% growth. PharmaEssentia had revenue of 3.06B in the quarter ending December 31, 2024, with 85.90% growth.
Revenue
9.73B
Revenue Growth
+90.67%
P/S Ratio
17.04
Revenue / Employee
74.31M
Employees
131
Market Cap
165.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | 557.26M | 251.57M | 82.29% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |
| Center Laboratories | 1.62B |
PharmaEssentia News
- 2 months ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga